| Issue Date | Title | Author(s) | Source | scopus | WOS | Fulltext/Archive link |
| 2021 | D614g substitution of sars-cov-2 spike protein increases syncytium formation and virus titer via enhanced furin-mediated spike cleavage | Cheng, Ya Wen; TAI-LING CHAO ; Li, Chiao Ling; Wang, Sheng Han; Kao, Han Chieh; Tsai, Ya Min; HURNG-YI WANG ; Hsieh, Chi Ling; Lin, You Yu; PEI-JER CHEN ; SUI-YUAN CHANG ; Yeh, Shiou-Hwei | mBio | 20 | 18 | |
| 2022 | Design, synthesis and biological evaluations of niclosamide analogues against SARS-CoV-2 | Juang, Yu-Pu; Chou, Yu-Ting; Lin, Ru-Xian; Ma, Hsiu-Hua; TAI-LING CHAO ; Jan, Jia-Tsrong; SUI-YUAN CHANG ; Liang, Pi-Hui | European journal of medicinal chemistry | 8 | 7 | |
| 2008 | Determination of human rotavirus VP6 genogroups I and II by reverse transcription-PCR | Lin Y.-P.; CHUAN-LIANG KAO ; SUI-YUAN CHANG ; Taniguchi K.; Hung P.-Y.; Lin H.-C.; LI-MIN HUANG ; Huang H.-H.; Yang J.-Y.; Lee C.-N. | Journal of Clinical Microbiology | 13 | 12 | |
| 2012 | Differential clinical and virologic impact of hepatitis B virus genotypes B and C on HIV-coinfected patients receiving lamivudine-containing highly active antiretroviral therapy | WANG-HUEI SHENG ; CHIEN-CHING HUNG ; SUI-YUAN CHANG ; CHUN-JEN LIU ; Chen M.-Y.; SZU-MIN HSIEH ; JIA-HORNG KAO ; PEI-JER CHEN ; SHAN-CHWEN CHANG | Clinical Infectious Diseases | 13 | 12 | |
| 2013 | Differential impact of resistance-associated mutations to protease inhibitors and nonnucleoside reverse transcriptase inhibitors on HIV-1 replication capacity | SZU-MIN HSIEH ; SUNG-CHING PAN ; SUI-YUAN CHANG ; CHIEN-CHING HUNG ; WANG-HUEI SHENG ; Chen M.-Y.; SHAN-CHWEN CHANG | AIDS Research and Human Retroviruses | 2 | 2 | |
| 1999 | Differential stability of the mRNA secondary structures in the frameshift site of various HIV type 1 viruses | SUI-YUAN CHANG ; Sutthent R.; Auewarakul P.; Apichartpiyakul C.; Essex M.; Lee T.-H. | AIDS Research and Human Retroviruses | 12 | 11 | |
| 2020 | Differentiation of cytopathic effects (CPE) induced by influenza virus infection using deep convolutional neural networks (CNN) | Wang T.-E.; TAI-LING CHAO ; Tsai H.-T.; Lin P.-H.; Tsai Y.-L.; SUI-YUAN CHANG | PLoS Computational Biology | 3 | 4 | |
| 2009 | Do we still need lead-in dosing of Nevirapine in HIV-infected patients who are receiving rifampicin-containing antituberculous therapy? | SUI-YUAN CHANG ; SHU-WEN LIN ; CHIEN-CHING HUNG | Clinical Infectious Diseases | 3 | 1 | |
| 2018 | Dolutegravir-rilpivirine coformulation | HSIN-YUN SUN ; SUI-YUAN CHANG ; CHIEN-CHING HUNG | Current Opinion in HIV and AIDS | 5 | 4 | |
| 2022 | Drug Repurposing for the Identification of Compounds with Anti-SARS-CoV-2 Capability via Multiple Targets | Yu, Pei-Chen; Huang, Chen-Hao; Kuo, Chih-Jung; Liang, Po-Huang; Wang, Lily Hui-Ching; Pan, Max Yu-Chen; SUI-YUAN CHANG ; TAI-LING CHAO ; Ieong, Si-Man; Fang, Jun-Tung; Huang, Hsuan-Cheng; HSUEH-FEN JUAN | Pharmaceutics | 3 | 3 | |
| 2020 | Dynamics of anti-SARS-Cov-2 IgM and IgG antibodies among COVID-19 patients | Lee Y.-L.; Liao C.-H.; Liu P.-Y.; Cheng C.-Y.; Chung M.-Y.; Liu C.-E.; SUI-YUAN CHANG ; PO-REN HSUEH | Journal of Infection | 103 | 84 | |
| 2020 | Effectiveness of half-a-tablet efavirenz plus 2 nucleos(t)ide reverse-transcriptase inhibitors as maintenance therapy with the guidance of therapeutic drug monitoring among virologically suppressed HIV-positive patients: A prospective study | Huang S.-H.; SHU-WEN LIN ; SUI-YUAN CHANG ; Lin Y.-T.; HSIN-YUN SUN ; Liu W.-C.; Su Y.-C.; CHIEN-CHING HUNG ; SHAN-CHWEN CHANG | Journal of Microbiology, Immunology and Infection | 4 | 4 | |
| 2023 | Effectiveness of second-generation integrase strand-transfer inhibitor-based regimens for antiretroviral-experienced people with HIV who had viral rebound | Chen, Guan-Jhou; HSIN-YUN SUN ; SUI-YUAN CHANG ; SZU-MIN HSIEH ; WANG-HUEI SHENG ; YU-CHUNG CHUANG ; YU-SHAN HUANG ; KUAN-YIN LIN ; Liu, Wen-Chun; Su, Yi-Ching; CHIEN-CHING HUNG | Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi | 0 | 0 | |
| 2019 | Effectiveness of switching from protease inhibitors to dolutegravir in combination with nucleoside reverse transcriptase inhibitors as maintenance antiretroviral therapy among HIV-positive patients | Chen G.-J.; HSIN-YUN SUN ; SUI-YUAN CHANG ; ARISTINE CHENG ; YU-SHAN HUANG ; KUAN-YIN LIN ; YI-CHIA HUANG ; Su Y.-C.; Liu W.-C.; CHIEN-CHING HUNG | International Journal of Antimicrobial Agents | 18 | 17 | |
| 2012 | An efficient, mild and scalable synthesis of bioactive compounds containing the angelicin scaffold | Shiao H.-Y.; Kuo C.-C.; Horng J.-T.; Shih S.-R.; SUI-YUAN CHANG ; Liao C.-C.; Hsu J.-T.A.; Amancha P.K.; Chao Y.-S.; Hsieh H.-P. | Journal of the Chinese Chemical Society | 5 | 5 | |
| 2023 | Elicitation of potent neutralizing antibodies in obese mice by ISA 51-adjuvanted SARS-CoV-2 spike RBD-Fc vaccine | Li, Chia-Jung; Jiang, Chung-Lin; TAI-LING CHAO ; Lin, Shiau-Yu; Tsai, Ya-Min; Chao, Chong-Syun; Su, Yu-Ting; Chen, Chun-Jen; SUI-YUAN CHANG ; FU-JUNG LIN ; SHIH-CHUNG CHANG | Applied microbiology and biotechnology | 1 | 1 | |
| 2011 | Emerging HIV-1 resistance to tipranavir and darunavir in patients with virological failure to first-generation protease inhibitors in Taiwan | SZU-MIN HSIEH ; SUI-YUAN CHANG ; CHIEN-CHING HUNG ; WANG-HUEI SHENG ; Chen M.-Y.; SHAN-CHWEN CHANG | International Journal of STD and AIDS | 2 | 2 | |
| 2020 | Endo-Lysosomal Cation Channels and Infectious Diseases | Chao, Yu-Kai; SUI-YUAN CHANG ; Grimm, Christian | Reviews of physiology, biochemistry and pharmacology | 13 | 0 | |
| 2022 | Endolysosomal cation channels point the way towards precision medicine of cancer and infectious diseases | CHENG-CHANG CHEN ; Krogsaeter, Einar; CHING-YING KUO ; MIN-CHUAN HUANG ; SUI-YUAN CHANG ; Biel, Martin | Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie | 5 | 4 | |
| 2020 | Enhancement of the IFN-β-induced host signature informs repurposed drugs for COVID-19 | Huang, Chen-Tsung; TAI-LING CHAO ; Kao, Han-Chieh; Pang, Yu-Hao; Lee, Wen-Hau; Hsieh, Chiao-Hui; SUI-YUAN CHANG ; Huang, Hsuan-Cheng; Juan, H.-F. | Heliyon | 16 | 15 | |
